Clinical trials: Optimized Treatment
Chronic Pain
POP SINGER Randomized Clinical Trial
Conduct a feasibility randomized controlled trial (N = 130, 65 per group) comparing the POPSINGER music therapy (MT) intervention to yoga.
- Trial name
- POP SINGER RCT (NCT07756541)
- Testing
- Yoga, Music Therapy
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University Hospitals Cleveland Medical Center
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- EARLYmyo-LVT (NCT03764241)
- Testing
- Rivaroxaban, Vitamin K Antagonist
- Where
- China
- Volunteers
- 280 people
- Sponsor
- RenJi Hospital
HIV Infections
Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients
The purpose of this study is to evaluate the efficacy of raltegravir with optimized background therapy (OBT) in multiple-experienced HIV infected patients, measured by the proportion of patients with undetectable viral load and…
- Trial name
- NCT01190124
- Volunteers
- 151 people
- Sponsor
- Doroana, Maria Manuela, M.D.
Systemic Mycosis
Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections
Invasive fungal infections (IFI) in immunocompromised patients pose a major challenge for diagnostics designed to permit timely onset of appropriate treatment.
- Trial name
- FUNGITECT (NCT02492594)
- Testing
- Peripheral blood sampling
- Where
- 7 sites in Austria, Netherlands and 1 more
- Volunteers
- 244 people
- Sponsor
- St. Anna Kinderkrebsforschung
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not…
- Trial name
- NCT03710421
- Testing
- CS1-CAR T Therapy, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 1 (NCT00098306)
- Testing
- Maraviroc (UK-427,857), Optimized Background Therapy
- Where
- 22 sites in United States, Canada
- Volunteers
- 601 people
- Sponsor
- ViiV Healthcare
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Heart Failure
Conduction System Pacing Optimized Therapy
The purpose of the CSPOT study is to determine the best mode of cardiac resynchronization therapy (CRT) pacing for different populations of CRT patients, comparing traditional biventricular or left ventricular pacing (BiV)…
- Trial name
- CSPOT (NCT04905290)
- Testing
- Left ventricular coronary sinus (BiV) configuration, Conduction system pacing-only configuration, Conduction System Pacing Optimized Therapy (CSPOT) configuration
- Where
- 12 sites in United States, Ireland and 2 more
- Volunteers
- 60 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
HIV
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
- Trial name
- NCT01836068
- Testing
- Enfuvirtide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for…
- Trial name
- PRO140 (NCT02483078)
- Testing
- PRO 140, Optimized Background Regimen
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- CytoDyn, Inc.
Bladder Cancer
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Bladder cancer (BC), the second most common urological malignancy, is an important public health issue. One of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which…
- Trial name
- NCT01675219
- Testing
- white light TUR-BT, blue light TUR-BT, optimized MMC
- Where
- 10 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Turku University Hospital
HIV Infections
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
The purpose of this study is to compare the change in viral load (amount of HIV in the blood) of patients who receive T-20 with selected anti-HIV drugs to that of patients who receive only selected anti-HIV drugs.
- Trial name
- NCT00008528
- Testing
- Enfuvirtide
- Where
- 37 sites in United States, Canada
- Volunteers
- 525 people
- Sponsor
- Hoffmann-La Roche
Attention Deficit Hyperactivity Disorder
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a laboratory classroom setting.
- Trial name
- NCT02493777
- Testing
- HLD200 methylphenidate hydrochloride (MPH) Capsules
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Stroke
Robot-Enhanced Stroke Therapy Optimizes Rehabilitation (RESTORE)
The purpose of this study is to investigate two aspects of robotic therapy after stroke. One goal is to determine if early robotic rehabilitation of the upper limb (beginning 5-9 days post-stroke) is more effective than later…
- Trial name
- RESTORE (NCT04201613)
- Testing
- Robotic exoskeleton, Usual Care
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University of Calgary
Arrythmia
Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study
Study to evaluate the safety and procedural performance of the KODEX - EPD System when used in the treatment of cardiac arrhythmias.
- Trial name
- PSOT-PMCF (NCT03481413)
- Testing
- Ablation
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 566 people
- Sponsor
- EPD Solutions, A Philips Company
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00660387
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 14 sites in United States, New Zealand
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Antibody-drug Conjugates, HER2-low Breast Cancer
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs).
- Conditions
- Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
- Trial name
- NCT06877416
- Testing
- Non-intervention research
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-sen University
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00551330
- Testing
- Vicriviroc
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis
Re-evaluating the Duration in Children of TB Treatment
Current tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment…
- Trial name
- REDUCE TB (NCT07656012)
- Testing
- Rifampicin, Isoniazid, Pyrazinamide
- Where
- Peru
- Volunteers
- 230 people
- Sponsor
- University of Wisconsin, Madison
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00523211
- Testing
- Vicriviroc
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC